Re-engineering of CYP2C9 to probe acid-base substrate selectivity

Drug Metabolism and Disposition

Volumn 36, Issue 10, 2008, Pages 1992-1997

  Tai, Guoying ^a,c   Dickmann, Leslie J ^a,d   Matovic, Nicholas ^b   DeVoss, James J ^b   Gillam, Elizabeth M J ^b   Rettie, Allan E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GLAXOSMITHKLINE   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARAGINE; ASPARTIC ACID; CYTOCHROME P450 2C9; DICLOFENAC; GLUTAMIC ACID; IBUPROFEN; IBUPROFEN AMINE; LIGAND; PROPRANOLOL; PYRENE; UNCLASSIFIED DRUG; WARFARIN;

ACIDITY; ALKALINITY; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CATALYSIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ENGINEERING; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HYDROXYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACIDS; ALKALIES; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; DNA PRIMERS; HEME; HUMANS; MUTAGENESIS; PROTEIN ENGINEERING; SPECTROPHOTOMETRY, ULTRAVIOLET; SUBSTRATE SPECIFICITY;

EID: 52949154604     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022186     Document Type: Article

References (28)

1. Bush E and Trager WF (1983) High-yield synthesis of warfarin and its phenolic metabolites: new compounds. J Pharm Sci 72:830-831.
2. Davies C, Witham K, Scott JR, Pearson A, DeVoss JJ, Graham SE, and Gillam EM (2004) Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9). Drug Metab Dispos 32:431-436.
3. Dickmann LJ, Locuson CW, Jones JP, and Rettie AE (2004) Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol Pharmacol 65: 842-850.
4. Ekroos M and Sjögren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 103:13682-13687.
5. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MM, Simula AP, Ackland MJ, Sternberg MJ, Lennard MS, Tucker GT, et al. (1995) Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 270:29055-29058.
6. Estabrook RW and Werringloer J (1978) The measurement of difference spectra: application to the cytochromes of microsomes. Methods Enzymol 52:212-220.
7. Flanagan JU, McLaughlin LA, Paine MJ, Sutcliffe MJ, Roberts GC, and Wolf CR (2003) Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity. Biochem J 370:921-926.
8. Guengerich FP, Miller GP, Hanna IH, Martin MV, Leger S, Black C, Chauret N, Silva JM, Trimble LA, Yergey JA, et al. (2002) Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 41:11025-11034.
9. Haining RL, Jones JP, Henne KR, Fisher MB, Koop DR, Trager WF, and Rettie AE (1999) Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry 38:3285-3292.
10. He M, Korzekwa KR, Jones JP, Rettie AE, and Trager WF (1999) Structural forms of phen-procoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 372:16-28.
11. Henne KR, Kunze KL, Zheng YM, Christmas P, Soberman RJ, and Rettie AE (2001) Covalent linkage of prosthetic heme to CYP4 family P450 enzymes. Biochemistry 40:12925-12931.
12. Jung F, Griffin KJ, Song W, Richardson TH, Yang M, and Johnson EF (1998) Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. Biochemistry 37:16270-16279.
13. Klose TS, Ibeanu GC, Ghanayem BI, Pedersen LG, Li L, Hall SD, and Goldstein JA (1998) Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. Arch Biochem Biophys 357:240-248.
14. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
15. Melet A, Assrir N, Jean P, Pilar Lopez-Garcia M, Marques-Soares C, Jaouen M, Dansette PM, Sari MA, and Mansuy D (2003) Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch Biochem Biophys 409:80-91.
16. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
17. Muralidhara BK, Negi S, Chin CC, Braun W, and Halpert JR (2006) Conformational flexibility of mammalian cytochrome P450 2B4 in binding imidazole inhibitors with different ring chemistry and side chains. Solution thermodynamics and molecular modeling. J Biol Chem 281:8051-8061.
18. Nelson WL and Burke TR Jr (1978) Pathways of propranolol metabolism. Use of the stable isotope twin-ion GC-MS technique to examine the conversion of propranolol to propranolol-diol by 9000g rat liver supernatant. Res Commun Chem Pathol Pharmacol 21:77-85.
19. Paine MJ, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GC, and Wolf CR (2003) Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 278:4021-4027.
20. Rettie AE and Jones JP (2005) Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45:477-494.
21. Ridderström M, Masimirembwa C, Trump-Kallmeyer S, Ahlefelt M, Otter C, and Andersson TB (2000) Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. Biochem Biophys Res Commun 270:983-987.
22. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, et al. (2006) Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614-7622.
23. Talaat RE and Nelson WL (1988) Regioisomeric aromatic dihydroxylation of propranolol. Synthesis and identification of 4,6- and 4,8-dihydroxypropranolol as metabolites in the rat and in man. Drug Metab Dispos 16:212-216.
24. Tsugeno Y and Ito A (1997) A key amino acid responsible for substrate selectivity of monoamine oxidase A and B. J Biol Chem 272:14033-14036.
25. Upthagrove AL and Nelson WL (2001) Importance of amine pKa and distribution coefficient in the metabolism of fluorinated propranolol analogs: metabolism by CYP1A2. Drug Metab Dispos 29:1389-1395.
26. Wada Y, Mitsuda M, Ishihara Y, Watanabe M, Iwasaki M, and Asahi S (2008) Important amino acid residues that confer CYP2C19 selective activity to CYP2C9. J Biochem, in press.
27. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 279:35630-35637.
28. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683-686.